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Abstract
The scientific community's reliance on active-controlled trials is steadily increasing, as widespread
agreement emerges concerning the role of these trials as viable alternatives to placebo trials. These
trials present substantial challenges with regard to design and interpretation as their complexity
increases, and the potential need for larger sample sizes impacts the cost and time variables of the
drug development process. The potential efficacy and safety benefits derived from these trials may
never be demonstrated by other methods. Active-controlled trials can develop valuable data to
inform both prescribers and patients about the dose- and time-dependent actions of any new drug
and can contribute to the management and communication of risks associated with the relevant
therapeutic products.
Background
In an era of cost containment, the need for rigorous exam-
ination of the cost-effectiveness of drugs, as well as their
clinical effectiveness, is widely recognized not only by
governments but also by the pharmaceutical industry [1-
4]. Messages framed differently, but with the same basic
content, have reached the community of prescribing phy-
sicians, who have come to understand that, although an
effective drug may be prescribed for patients who would
benefit from it, unless the drug is cost-effective, the
resources that are expended might produce greater bene-
fits for other patients. Such messages and updated recom-
mendations to prescribing doctors, in addition to results
derived from recent large, randomized trials, continue to
have only minimal, if any, impact on the prescribing hab-
its of doctors.
The latest such example [5] concerns the outcomes of the
Antihypertensive and Lipid-Lowering Treatment to Pre-
vent Heart Attack Trial (ALLHAT), indicating that diuretics
could be more effective than angiotensin-converting
enzyme (ACE) inhibitors or calcium channel blockers in
the treatment of hypertension, and at a much lower cost
[6]. Despite this convincing evidence, a study presented at
the annual conference of the American Heart Association
in March 2004 showed that spending on antihypertensive
drugs essentially doubled (from approximately $6 billion
to approximately $12 billion) between 1990 and 2002.
The explanation most commonly offered is that "doctors
selected the more costly antihypertensive agents."
Since cost-effectiveness is conventionally required for
evaluating the efficacy of alternative healthcare interven-
tions, the perspective commonly taken is that of the
health services [7]. Therefore, establishing the superiority
or equivalence of a new intervention relative to the stand-
ard one has been extended not only to new drug entities,
but also to generic versions of innovator drugs [8],
Published: 17 August 2004
Current Controlled Trials in Cardiovascular Medicine 2004, 5:8 doi:10.1186/1468-6708-5-8
Received: 13 April 2004
Accepted: 17 August 2004
This article is available from: http://cvm.controlled-trials.com/content/5/1/8
© 2004 Pater; licensee BioMed Central Ltd. 
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Current Controlled Trials in Cardiovascular Medicine 2004, 5:8 http://cvm.controlled-trials.com/content/5/1/8
Page 2 of 7
(page number not for citation purposes)
surgical techniques [9], medical devices [10], and such
diverse factors as medical protocols [11].
Cost-effectiveness and clinical effectiveness should be
pursued simultaneously to ensure that health care is effi-
cient, ethical, and beneficial to patients. This paper deals
with only one aspect of clinical effectiveness: drug treat-
ment benefit and how it may be ascertained from claims
of therapeutic equivalence.
Ethical Issues
The basis for the scientific and ethical underpinnings for
the design and conduct of randomized clinical trials is the
uncertainty principle, which states that a patient should be
enrolled in a randomized controlled trial only when sub-
stantial uncertainty exists as to which of the trial treat-
ments would benefit the patient more [12]. From this
principle derives the fundamental ethical challenge of
equivalence trials, reflected in the researcher's explicitly
expressed belief that "the new drug might be not different
from the old drug," a fact that should be acknowledged in
the consent process whereby trial subjects are informed
that "it is not known which drug is better or whether they
are the same."
Nevertheless, demonstrating equivalence of the drugs
being compared implies starting from the assumption
that the new drug is better. In other words, the hypothesis
to be tested in equivalence trials (and the hypothesis that
is refuted if equivalence is shown) is that one treatment is
superior to the other. Altruistic patients are more likely to
agree to participate in such a trial, whereas other, less
altruistic patients are more likely to decline participation,
as their interest lies in treatments with proven efficacy.
Obviously, this situation is more patient-favorable than
are placebo-controlled trials, in which the individual
patient's well-being may be subordinated to the good of
others [13,14]. Placebo-controlled trials are still used
extensively to demonstrate the effectiveness of new drugs;
however, a paradigm shift appears to be steadily emerging
in this area [15,16]. Speaking metaphorically, Urquhart
stated that placebos are predestined to be "roadkill on the
highway of medical progress" [17].
For circumstances in which no increased risk for patients
is foreseen, use of placebo-controlled trials seems appro-
priate and ethical, provided the patients are fully
informed and that they give their written, informed con-
sent. However, if these patients and their doctors were to
find the placebo-controlled studies inappropriate, and if
they were to exercise their option in large numbers, these
studies would become unfeasible, regardless of the ethical
justifications, scientific considerations, views of the trial
sponsor, or, ultimately, the expectations of regulatory
authorities.
Apart from the extreme opinions that challenge the pla-
cebo-controlled trials as unethical [18-24] and those that
advocate proactive use of the active-controlled equiva-
lence trials [25,26,31] or question their scientific merits
[16,26-32], a balanced approach is needed (i.e., one that
recognizes the use of placebos in instances wherein effi-
cacy cannot otherwise be demonstrated, and the use of
active-controlled trials as the design of first choice when
scientifically sound circumstances require it). Simultane-
ous use of both alternatives might be necessary in selected
cases.
The issue of assay sensitivity
Defined as "the ability of a study to distinguish between
active and inactive treatment," assay sensitivity is the sine
qua non for the validity of equivalence claims derived from
any active-controlled equivalence/noninferiority study.
Methodological flaws affecting one or several of the spe-
cific elements inherent in assay sensitivity itself seem to
have been more a rule than an exception in many trials
carried out during the past decade. Illustrating this point
is a systematic review of trials published between 1992
and 1996 that claim equivalence [33]. In the review, the
authors showed that:
• 88 papers were evaluated for five equivalence-specific
methodological attributes.
• Only 45 (51%) of the 88 reports specifically identified
demonstration of equivalence as their aim; the others
attempted to show superiority or did not state any
research aim.
• An equivalence boundary was set and confirmed with an
appropriate statistical test in 23% of the reports; in 67% of
reports, equivalence was declared after a failed test for
comparative superiority; in 10%, the claim of equivalence
was not evaluated statistically.
• Sample sizes were calculated in advance in 33% of
reports.
• In 25% of reports, sample size was 20 patients per group
or fewer.
The main concern with such "equivalence claims" is cer-
tainly the risk of harm to patients, as poor sensitivity has
the potential to cause a type II error (false conclusion of
no efficacy) and thereby to thwart satisfaction of public
health needs for effective medicines.
Just as important as paying careful attention to all aspects
of assay sensitivity is acknowledging from the outset that
a large number of pharmaceutical products present sensi-
tivity problems. That is, agents otherwise known to beCurrent Controlled Trials in Cardiovascular Medicine 2004, 5:8 http://cvm.controlled-trials.com/content/5/1/8
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clinically effective are often indistinguishable from pla-
cebo in well-designed and well-conducted trials. For this
reason, such drugs are useless as comparators in active-
controlled trials. A typical example is ondansetron, an
antiemetic that, despite its known clinical effectiveness,
showed no effect in many placebo-controlled trials [34].
Claims of equivalence of a new antiemetic agent with
ondansetron would therefore be unreliable, given the lack
of assay sensitivity of ondansetron (despite many trials in
which it had proven to be superior in comparison with
placebo). Similar examples include agents belonging to
the class of antidepresssants, analgesics [35], beta-block-
ers used in postinfarct patients [36], antihypertensives,
ACE inhibitors used in patients with heart failure,
antianginal agents, and antihistamines.
The explanation for this serious problem lies in the great
variability of the random placebo effect, which at times
may profoundly confound the direction and the magni-
tude of treatment effects, especially in studies based on
small sample sizes [37]. Regarding the example of
ondansetron, the incidence of nausea and vomiting
ranged from 10% to 96% in the placebo-controlled trials.
Furthermore, regarding situations in which multiple trials
have demonstrated the efficacy of the active control when
compared to placebo, the potential exists for referral bias
due to eventual nonreporting of negative results. The risk
in such instances is that the smallest clinically relevant
effect of the control drug may not be valid [38].
Rationale for choice of active control
In contrast to the scenarios described above, equivalence
and noninferiority trials should be undertaken only when
a well-proven standard therapy exists (i.e., when the
intended control drug is accepted as the standard of care
for the particular indication). Investigators should be con-
fident that the efficacy of the control drug was proven to
be superior in a previous placebo-controlled trial and that
this efficacy will be preserved under the conditions of the
current trial (i.e., the control drug has an established, pre-
dictable and quantifiable effect). Doubts about the valid-
ity of these assumptions mean uncertainty as to whether
the two drugs in the current trial, which are allegedly
equivalent, really are effective to a similar degree, or are
equally ineffective, or cannot be evaluated definitively
because the trial design was inadequate to demonstrate
the real differences between the two agents.
The goal of showing equivalence
A recent editorial by Alderson [39] concluded as follows:
"We need to create a culture that is comfortable with esti-
mating and discussing uncertainty." This observation
applies especially to the field of equivalence/noninferior-
ity trials. Increasing the degree of certainty in these trials is
a matter of paying careful attention to the elements of
study design, conduct, and analysis – all supposed to mir-
ror as closely as possible the design, conduct, and analysis
performed in previous evaluations of the current active
control against placebo. Such trials should be reported in
a transparent and explicit fashion, to acknowledge that
they are not really equivalent to superiority trials [40].
The primary objective of equivalence/noninferiority trials
is to demonstrate that the efficacy of the new treatment
matches that of the control treatment. However, "equiva-
lence" should not be interpreted to mean 100% (absolute
equivalence can never be demonstrated), but that despite
some degree of difference, the two agents are clinically
indistinguishable. Closer scrutiny should be afforded the
secondary objectives of the study, as they might demon-
strate some sort of superiority over the control, such as a
more favorable safety profile, easier administration, or
reduced cost. Alternatively, results might indicate that the
new agent would be a reliable second-line treatment.
All too often in the past, when trials that were designed to
demonstrate the superiority of an agent over its compara-
tor failed to reject the null hypothesis (i.e., a statistically
significant difference was not demonstrated), results were
interpreted as proof of the equivalence of the two drugs. A
dangerous mismatch of the goals of the superiority and
equivalence trials arises when the general reasoning
employed in planning and evaluating superiority trials is
simply extrapolated to active-controlled trials.
The aim of the superiority trial is to rule out the equality
of the two agents being compared by rejecting the null
hypothesis that the two agents are the same. Failure to
reject the null hypothesis does not mean that equivalence
can be assumed. Lack of superiority might be consistent
with equivalence but does not prove it. In other words,
"absence of evidence of a difference is not evidence of
absence of a difference" [41].
In equivalence trials, the goal is to rule out all differences
of clinical importance between the two agents being com-
pared. This goal is accomplished by rejecting the null
hypothesis that the smallest difference of clinical impor-
tance exists in favor of the standard-of-care regimen (i.e.,
in favor of the active control in the current trial). There-
fore, establishing equivalence is contingent upon deter-
mining what specifically and precisely constitutes a
clinically important difference. This process translates
into the need to prove that the two interventions do not
differ by more than a certain amount, defined as the
"equivalence margin" (i.e., the tested agent is not inferior
to the active control by more than the predefined margin).Current Controlled Trials in Cardiovascular Medicine 2004, 5:8 http://cvm.controlled-trials.com/content/5/1/8
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Methodological requirements
Patient compliance with therapy
To assure the adequacy of the compliance component of
assay sensitivity, prescreening of subjects selected to par-
ticipate in active-controlled trials is necessary, as is reliable
assessment of patient compliance with the trial require-
ments by means of appropriate methodologies [42,43].
Commonly, compliance is defined as the degree of corre-
spondence between the patient's current dosing history
and the prescribed drug regimen [44]. This seemingly sim-
ple definition covers the wide variability in patient com-
pliance in the use of prescribed drugs. The degree of drug
exposure has an impact on important clinical outcome
variables and cost-effectiveness parameters [45,46].
Knowledge of the drug's kinetics and dynamics may allow
pharmacokinetic/pharmacodynamic modeling, to
address the consequences of temporal dosing patterns
that result from variations in patient compliance with the
recommended treatment regimen [17].
The most compelling example of treatment noncompli-
ance occurs with antihypertensive medications. Noncom-
pliance seems to be the main reason that blood pressure
is adequately controlled in fewer than one fourth of
patients treated for hypertension, both in the US and in
European countries [47,48]. The classical "pill count"
method of assessment grossly overestimates patient com-
pliance, as self-reporting of medication use is highly
skewed toward reports of excellent compliance [49] Over-
reliance on inaccurate self-reports of compliance in
research studies can result in misleading conclusions
about both the efficacy of treatment and the dose-
response relationships [48]. Electronic pill boxes that reg-
ister the date and time of each access have become the
"gold standard" and could be a valuable complement to
conventional self-reporting of compliance [50,51]. Fur-
thermore, compliance with the protocol-specified regi-
men can be improved by prescreening patients who are
eligible for recruitment to active-controlled studies, with
the aim of assessing the ability of individuals to comply
with study-specific requirements.
Concomitant medication
Use of co-medication during active-controlled studies,
whether the result of self-medication or prescription med-
ication, can distort the study's final results. Co-medication
can interfere with response to the tested drug or the con-
trol drug, or it can influence the trial endpoints and lead
to false-positive conclusions of equivalence. Use of non-
trial medication is quite common in clinical trials in gen-
eral and should be assessed and minimized, particularly
in active-controlled studies.
Patients' baseline characteristics and outcome features
A basic assumption is that the active agent in an equiva-
lence/noninferiority study should have retained its
known (historical) effect, demonstrated in a previous pla-
cebo-controlled comparison. Patients participating in the
current study should be as similar as possible to the
patients in the placebo-controlled trial with respect to all
baseline values and treatment variables that might influ-
ence outcome. These variables include symptoms, signs,
risk factors, morbidity, compliance with therapy, respon-
siveness to drug effects, nonuse of prohibited concomi-
tant medication, consistent diagnostic criteria, inclusion
and exclusion criteria, unbiased assessment of endpoints,
and reasons for dropping out. Failure to achieve this sim-
ilarity from the outset, failure to ensure high-quality study
conduct, or both, can introduce bias into the study and
compromise assay sensitivity.
The classical method to minimize systematic differences
between study groups is randomization, (i.e., random allo-
cation of patients to test or control groups). Further, dou-
ble blinding is intended to minimize potential biases
resulting from differences in management, treatment, or
assessment of patients, or differences in interpretation of
results that could arise as a result of the subject's or inves-
tigator's knowledge of the assigned treatment.
The type and frequency of outcome events in the current
study are expected to be similar to those in the placebo-
controlled comparison. Substantial differences, resulting
most often from an imbalance in one or more of the vari-
ables mentioned above would render interpretation of
differences between the new therapy and the active con-
trol very difficult. For example, because of lower baseline
blood pressure values and fewer associated risk factors,
patients in a hypertension study may display fewer out-
come events.
Choice and importance of outcome variables
Equivalence trials are commonly designed to demonstrate
that the test treatment is similar in efficacy to the active
control, the assumption being that the control treatment
is effective under the conditions of the current trial. In
reality, however, most equivalence trials are actually non-
inferiority trials, attempting to show that the new drug is
not less effective than the control by more than the
defined amount (margin). Presence of assay sensitivity is
essential for interpretation of such a study. In cases with
doubtful assay sensitivity, a three-arm study design (test
drug, active control, and placebo) might be optimal. Apart
from being more complex and requiring a larger sample
size, such a trial offers the advantage of measuring the
effect of the test drug versus placebo while allowing com-
parison of the test drug and active control in a setting in
which assay sensitivity is established by the active control-Current Controlled Trials in Cardiovascular Medicine 2004, 5:8 http://cvm.controlled-trials.com/content/5/1/8
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versus-placebo comparison. By making the active groups
in such trials larger than the placebo groups, it is possible
to increase the precision of the active drug comparison
while minimizing the chance that patients will be ran-
domly assigned to placebo groups. Furthermore, this
design allows distinction between adverse events due to
the drug and those due to underlying disease ("back-
ground noise") [52].
As mentioned earlier, equivalence/noninferiority trials
should not only focus on efficacy, but also should pro-
spectively define an analytical plan for safety assessment
as a secondary objective. Accordingly, appropriate statisti-
cal power to detect adverse effects is a necessity, as is col-
lection of data on the comparative safety of each
treatment. Failure to meet these requirements not only
undermines the chance to exploit a potentially favorable
safety profile of the test drug versus the control, but also
presents the risk of missing dangerous signals with regard
to safety. A recent example relates to mibefradil, a calcium
inhibitor that appeared to have an excellent safety profile
until postmarketing surveillance revealed cases of sudden
death in patients at high risk for polymorphic ventricular
tachycardia or patients in whom concomitantly adminis-
tered drugs either inhibited mibefradil metabolism or
otherwise amplified its cardiac risk [53]. A more recent
experience with COX-2 inhibitors illustrates another sig-
nificant problem in current evaluations of new drug
safety. In the VIGOR study [54], the extensively marketed
product rofecoxib appeared to be inferior to naproxen
with regard to the frequency of cardiovascular thrombotic
events, raising the question of rofecoxib's inferiority ver-
sus naproxen's superiority to an imputed placebo [55].
Confidence interval and sample size
The margin (∆) itself clearly communicates a judgment as
to what is and is not important. The margin defines the
largest difference that is clinically acceptable. Setting the
margin is critical to the design of both equivalence and
noninferiority trials, and it is commonly established for
the purpose of excluding a clinically important difference
between treatments. However, what constitutes such a dif-
ference may vary widely for each patient and clinician and
might fall below the margins set by the designer of the
trial. For that reason, careful clinical judgment and statis-
tical reasoning should be exercised in selecting a meaning-
ful difference to be ruled out; furthermore, this difference
should be specified and justified a priori in all equiva-
lence/noninferiority trials. At the very least, the equiva-
lence margin should be smaller than the lower 95%
confidence limit for the absolute risk difference observed
between standard therapy and placebo in the relevant
superiority trial [31]. That is, this lower boundary of the
95% confidence interval is the smallest expected effect of
the control over the placebo, and it should exceed the
established margin [29,38].
Confidence interval is the method of choice to interpret
equivalence and noninferiority trials. It defines a range for
the possible true differences between the test drug and the
active control. If every point within this range reflects a
difference that is clinically nonrelevant, then the two
agents may be considered equivalent. In other words, for
an equivalence trial, the two-sided 95% confidence inter-
val – defining the range of possible differences between
the test and the control agent – should lie entirely within
the interval (-∆ to +∆) (Fig. 1, lines c, d, and e).
For a noninferiority trial, the effect of the new drug may
be shown to be similar to or greater than that of the con-
trol. The possible difference of interest occurs only in the
- ∆ direction, and the 95% confidence interval should lie
entirely to the right of the - ∆ value (Fig. 1, line a). A p
value associated with the null hypothesis of noninferior-
ity can be calculated.
A trial that is intended to demonstrate noninferiority may
actually allow a claim of superiority for the test drug. In
such a case, the one-sided 95% confidence interval lies to
the right of not only the - ∆ but also the zero line (Fig. 1,
line g). A p value can be calculated to verify whether the
superiority test is sufficiently small to reject the hypothesis
of no difference at the 5% α level (p < 0.05). A claim of
superiority, however, would imply a careful assessment of
the test drug's safety profile, which should be similar to or
better than that of the control to increase the strength of
the evidence in favor of superiority. A less favorable safety
profile raises the question of whether the claimed superi-
ority outweighs the eventual adverse effects and therefore
requires a careful quantification of the overall risk-benefit
in clinical terms. This latter emphasis is meant as a
reminder that claimed superiority of a test agent in the
context of a noninferiority trial is, in fact, superiority to
"no treatment," based on the proven superiority of the
control agent against placebo in a previous trial.
Another possible scenario is that of a superiority trial that
fails to detect a significant difference between the two
agents being compared. An investigator who anticipates
this outcome at the outset of the trial may want to down-
grade the goal from superiority to noninferiority. That
change is legitimate, provided that a noninferiority mar-
gin has been prospectively defined and the 95% confi-
dence interval shown to lie to the right of the - ∆ (Fig. 1,
lines a and f). A post hoc definition of the margin is not
acceptable.
For calculating sample size, values should be specified for
the range of equivalence (∆), and the α (type I error) andCurrent Controlled Trials in Cardiovascular Medicine 2004, 5:8 http://cvm.controlled-trials.com/content/5/1/8
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β (type II error) values should be selected on the basis of
the same principles as for comparative trials. The distinc-
tion between one-sided and two-sided tests of statistical
significance carries over into the confidence interval
approach recommended by the Committee for Proprie-
tary Medicine Products (CPMP) guidelines [56,57], which
provide key information for making decisions about
equivalence/noninferiority.
Unlike superiority trials, in which intention-to-treat anal-
ysis is the rule, in equivalence/noninferiority trials both
intention-to-treat and per-protocol analysis should be
run. Both types of analysis would be expected to lead to
similar conclusions for a robust interpretation. In a recent
article, Gomberg-Maitland et al. [58] suggested the use of
standard guidelines for reporting equivalence/noninferi-
ority trials to facilitate qualitative assessment of the meth-
odology applied (Table 1).
Conclusions
Each year, major advances in drug discovery generate a
seemingly endless supply of new drugs in virtually all
therapeutic areas; however, in most cases these new drugs
provide only incremental improvement in efficacy, safety,
or the overall risk-benefit ratio. In addition, ethics-based
restrictions on the use of placebos as comparators have
enhanced the viability of equivalence and noninferiority
trials as viable alternatives for registration purposes, for
risk management once the drug is on the market, and for
a marked increase in confidence in the new drug on the
part of doctors and patients.
Given the complexity of these study designs, careful atten-
tion should be paid to the proper use of specific epidemi-
ological features so as to avoid methodological
deficiencies that may harm patients if clinically inferior
treatments are erroneously deemed equivalent to the
standard of care, or if potentially superior therapies are
discarded as merely "equivalent."
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